Nautilus Biotechnology, Inc.
As of Oct 22, 2026, Nautilus Biotechnology is in Stage 1, the basing phase, now in week 2 (since Oct 15, 2026). It closed at $2.60, 34.2% below its 52-week high and above its 200-day average, which is rising.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NAUT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NAUT among Biotechnology60th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …60 | NAUT | Stage 1 · wk 2 | 93 | +172.5% |
Nautilus Biotechnology: quick answers
What stage is Nautilus Biotechnology in?
As of Oct 22, 2026, Nautilus Biotechnology (NAUT) is in Stage 1, the basing phase. It entered Stage 1 on Oct 15, 2026 and is in week 2. What the four stages mean
Is Nautilus Biotechnology in an uptrend?
Not yet. Nautilus Biotechnology is in Stage 1, a base that can come before an uptrend. It trades 24.4% above its 200-day average, which is rising.
How far is Nautilus Biotechnology from its 52-week high?
Nautilus Biotechnology closed at $2.60 on Oct 22, 2026, 34.2% below its 52-week high of $3.95. Its 52-week low is $0.85.
How has Nautilus Biotechnology performed over the past year?
As of Oct 22, 2026, Nautilus Biotechnology is up 83.1% over the past year and up 36.1% so far in 2026.
Which sector and industry is Nautilus Biotechnology in?
Nautilus Biotechnology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.